, Tracking Stock Market Picks
Enter Symbol:
Acadia Pharmaceuticals Inc. (ACAD) [hlAlert]

down 64.86 %

Acadia Pharmaceuticals Inc. (ACAD) rated Sell with price target $6 by Brean Murray

Posted on: Tuesday,  May 6, 2008  8:25 AM ET by Brean Murray

Brean Murray rated Sell Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) on 05/06/2008. Previously Brean Murray rated Sell Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) on
11/06/2007., when the stock price was $13.32. Since then, Acadia Pharmaceuticals Inc. has gained 184.61% as of 01/25/2016's recent price of $37.91.
If you would have followed the previous Brean Murray's recommendation on ACAD, you would have lost 64.86% of your investment in 3002 days.

Acadia Pharmaceuticals Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule drugs for the treatment of central nervous system disorders. The Company is developing a portfolio consisting of its four product candidates, including pimavanserin, which is in Phase III development for the treatment of Parkinson?s disease psychosis. In addition, the Company has a product candidate in Phase II for chronic pain and a product candidate in Phase I for glaucoma, both in collaboration with Allergan, Inc., and ACP-106 in IND-track development. The Company?s product candidates include Pimavanserin, AGN-XX/YY, AC-262271 and ACP-106. The Company maintains two wholly owned subsidiaries: ACADIA Pharmaceuticals AB based in Malmo, Sweden and ACADIA Pharmaceuticals A/S based in Denmark.

Our equity research department is focused on fundamental analysis across the universe of over 200 small/mid cap stocks in our five target sectors. We are committed to providing proprietary action-oriented research to our institutional clients. Small cap growth focus. Our primary area of concentration is growth stocks with market capitalization of $200 million to $5 billion. Global perspective. We are covering U.S. listed stocks for companies domiciled in the U.S., China, Europe and Latin America, with our biggest concentration in the US and China. We were one of the first banks to aggressively expand our research to China and we believe we created one of the premier research franchises in small cap, U.S. listed Chinese companies to complement our strong domestic coverage. Disciplined stock selection. Our research analysts are focused on performing extensive bottoms up due diligence on companies under our coverage by leveraging their industry and management contacts. By combining our bottoms up work with our sector views we seek to generate a consistent flow of high conviction ideas for our clients. Diversified coverage. Our areas of expertise include technology, consumer, healthcare, resources and China small cap. We provide our clients with company-specific as well as sector-specific research across our target sectors.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
5/6/2008 8:25 AM Sell
7.99 6.00
as of 12/24/2008
1 Week up  12.84 %
1 Month up  1.04 %
3 Months up  12.03 %
1 YTD down  -5.55 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
11/6/2007 9:25 AM Sell
13.32 7.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy